Basic Information
SELTAVIR 30 CAPSULE 30MG
CAPSULE
Regulatory Information
SIN16669P
January 5, 2023
Prescription Only
Therapeutic
ORAL
August 10, 2023
June 3, 2025
XJ05AH02
Company Information
UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED
UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED
Active Ingredients
Strength: 30mg
Detailed Information
Contraindications
**Contraindications** Oseltamivir Capsules is contraindicated in patients with known hypersensitivity to Oseltamivir phosphate or to any component of the product.
Indication Information
Therapeutic indications _**Treatment of influenza**_ In patients one year of age and older who present with symptoms typical of influenza, when influenza virus is circulating in the community. Efficacy has been demonstrated when treatment is initiated within two days of first onset of symptoms. This indication is based on clinical studies of naturally occurring influenza in which the predominant infection was influenza A (see Pharmacodynamic properties – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). Based on limited pharmacokinetic and safety data, Oseltamivir Capsules can be used in children 6 to 12 months of age for treatment during a pandemic influenza outbreak. The treating physician should take into account the pathogenicity of the circulating strain and the underlying condition of the patient to ensure there is a potential benefit to the child. _**Prevention of influenza**_ - Post-exposure prevention in individuals one year of age or older following contact with a clinically diagnosed influenza case when influenza virus is circulating in the community. - The appropriate use of Oseltamivir Capsules for prevention of influenza should be determined on a case by case basis by the circumstances and the population requiring protection. In exceptional situations (e.g., in case of a mismatch between the circulating and vaccine virus strains, and a pandemic situation) seasonal prevention could be considered in individuals one year of age or older. _**Oseltamivir Capsules is not a substitute for influenza vaccination.**_ The use of antivirals for the treatment and prevention of influenza should be determined on the basis of official recommendations. Decisions regarding the use of antivirals for treatment and prophylaxis should take into consideration what is known about the characteristics of the circulating influenza viruses and the impact of the disease in different geographical areas and patient populations.